Скачать или смотреть MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma

Elranatamab (ELRA), a bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells, showed promising results in the MagnetisMM-3 trial for relapsed or refractory multiple myeloma (RRMM). The study assessed its efficacy and safety over an extended period, including outcomes after transitioning to dosing once every 4 weeks (Q4W).

Key Points:
ELRA induced deep and durable responses in BCMA-naive RRMM patients.
Primary endpoint: Objective Response Rate (ORR) was 61.0%, with 37.4% achieving complete response or better.
Median duration of response (DOR) not reached; 66.9% probability of maintaining response at 24 months.
Safety profile: Reduced dosing frequency to Q4W showed manageable adverse events (AEs), including infections and hematologic disorders.
Conclusion: ELRA demonstrates sustained efficacy and safety in heavily pretreated RRMM patients, supporting Q4W dosing as a potential safety improvement.

Authors:
H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
X/Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52...

Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.